Natural  ||| S:0 E:8 ||| JJ
killer  ||| S:8 E:15 ||| NN
cell  ||| S:15 E:20 ||| NN
cytotoxity  ||| S:20 E:31 ||| NNS
and  ||| S:31 E:35 ||| CC
course  ||| S:35 E:42 ||| NN
of  ||| S:42 E:45 ||| IN
illness  ||| S:45 E:53 ||| NN
in  ||| S:53 E:56 ||| IN
depressed  ||| S:56 E:66 ||| JJ
mood  ||| S:66 E:71 ||| NN
There  ||| S:71 E:77 ||| EX
is  ||| S:77 E:80 ||| VBZ
now  ||| S:80 E:84 ||| RB
some  ||| S:84 E:89 ||| DT
evidence  ||| S:89 E:98 ||| NN
that  ||| S:98 E:103 ||| IN
depressed  ||| S:103 E:113 ||| JJ
mood  ||| S:113 E:118 ||| NN
is  ||| S:118 E:121 ||| VBZ
associated  ||| S:121 E:132 ||| VBN
with  ||| S:132 E:137 ||| IN
activation  ||| S:137 E:148 ||| NN
of  ||| S:148 E:151 ||| IN
the  ||| S:151 E:155 ||| DT
immune  ||| S:155 E:162 ||| JJ
system ||| S:162 E:168 ||| NN
.  ||| S:168 E:170 ||| .
First ||| S:170 E:175 ||| NNP
,  ||| S:175 E:177 ||| ,
we  ||| S:177 E:180 ||| PRP
evaluated ||| S:180 E:189 ||| VBD
,  ||| S:189 E:191 ||| ,
within  ||| S:191 E:198 ||| IN
a  ||| S:198 E:200 ||| DT
cross-sectional  ||| S:200 E:216 ||| JJ
design ||| S:216 E:222 ||| NN
,  ||| S:222 E:224 ||| ,
NKCA  ||| S:224 E:229 ||| NNP
( ||| S:229 E:230 ||| -LRB-
in  ||| S:230 E:233 ||| IN
vitro ||| S:233 E:238 ||| CD
)  ||| S:238 E:240 ||| -RRB-
in  ||| S:240 E:243 ||| IN
49  ||| S:243 E:246 ||| CD
subjects  ||| S:246 E:255 ||| NNS
meeting  ||| S:255 E:263 ||| NN
inclusion  ||| S:263 E:273 ||| NN
criteria  ||| S:273 E:282 ||| NNS
either  ||| S:282 E:289 ||| CC
for  ||| S:289 E:293 ||| IN
a  ||| S:293 E:295 ||| DT
major  ||| S:295 E:301 ||| JJ
depressive  ||| S:301 E:312 ||| JJ
episode ||| S:312 E:319 ||| NN
,  ||| S:319 E:321 ||| ,
for  ||| S:321 E:325 ||| IN
dysthymia ||| S:325 E:334 ||| NN
,  ||| S:334 E:336 ||| ,
or  ||| S:336 E:339 ||| CC
for  ||| S:339 E:343 ||| IN
double  ||| S:343 E:350 ||| JJ
depression ||| S:350 E:360 ||| NN
.  ||| S:360 E:362 ||| .
We  ||| S:362 E:365 ||| PRP
found  ||| S:365 E:371 ||| VBD
that  ||| S:371 E:376 ||| DT
recent  ||| S:376 E:383 ||| JJ
and  ||| S:383 E:387 ||| CC
long  ||| S:387 E:392 ||| RB
depressive  ||| S:392 E:403 ||| JJ
episodes  ||| S:403 E:412 ||| NNS
( ||| S:412 E:413 ||| -LRB-
dysthymia ||| S:413 E:422 ||| LS
)  ||| S:422 E:424 ||| -RRB-
are  ||| S:424 E:428 ||| VBP
associated  ||| S:428 E:439 ||| VBN
with  ||| S:439 E:444 ||| IN
a  ||| S:444 E:446 ||| DT
lower  ||| S:446 E:452 ||| JJR
immunodepression ||| S:452 E:468 ||| NN
.  ||| S:468 E:470 ||| .
Second ||| S:470 E:476 ||| LS
,  ||| S:476 E:478 ||| ,
we  ||| S:478 E:481 ||| PRP
compared  ||| S:481 E:490 ||| VBD
two  ||| S:490 E:494 ||| CD
subset  ||| S:494 E:501 ||| NN
of  ||| S:501 E:504 ||| IN
subjects ||| S:504 E:512 ||| NNS
:  ||| S:512 E:514 ||| :
14  ||| S:514 E:517 ||| CD
patients  ||| S:517 E:526 ||| NNS
meeting  ||| S:526 E:534 ||| NN
criteria  ||| S:534 E:543 ||| NNS
of  ||| S:543 E:546 ||| IN
major  ||| S:546 E:552 ||| JJ
depression  ||| S:552 E:563 ||| NN
to  ||| S:563 E:566 ||| TO
14  ||| S:566 E:569 ||| CD
healthy  ||| S:569 E:577 ||| JJ
controls ||| S:577 E:585 ||| NNS
.  ||| S:585 E:587 ||| .
The  ||| S:587 E:591 ||| DT
data  ||| S:591 E:596 ||| NNS
show  ||| S:596 E:601 ||| VBP
a  ||| S:601 E:603 ||| DT
significant  ||| S:603 E:615 ||| JJ
improvement  ||| S:615 E:627 ||| NN
in  ||| S:627 E:630 ||| IN
major  ||| S:630 E:636 ||| JJ
depression  ||| S:636 E:647 ||| NN
when  ||| S:647 E:652 ||| WRB
compared  ||| S:652 E:661 ||| VBN
to  ||| S:661 E:664 ||| TO
controls  ||| S:664 E:673 ||| NNS
througout  ||| S:673 E:683 ||| VBP
a  ||| S:683 E:685 ||| DT
treatment  ||| S:685 E:695 ||| NN
combining  ||| S:695 E:705 ||| VBG
supportive  ||| S:705 E:716 ||| JJ
psychotherapy  ||| S:716 E:730 ||| NN
and  ||| S:730 E:734 ||| CC
8  ||| S:734 E:736 ||| CD
mg  ||| S:736 E:739 ||| CD
Reboxetineâ„¢ ||| S:739 E:750 ||| CD
.  ||| S:750 E:752 ||| .
